

## Antigenic Properties of preS2 Region of Hepatitis B Virus Envelope Proteins

Lee, Kee Nyung, Sang Chul Lee, Ki-Sun Kwon,  
Hong Keun Chung\* and Myeong-Hee Yu<sup>§</sup>

Genetic Engineering Center, Korea Institute of Science and Technology, P.O. Box 131,  
Cheongryang, Seoul, Korea

\*Dept. of Biochemistry, School of Medicine, Seoul National University,  
Chong-Ro Ku, Seoul, Korea

### B 형 간염바이러스 표면단백질 중 preS2 부위의 항원적 특성

이기녕·이상철·권기선·정홍근\*·유명희<sup>§</sup>

<sup>§</sup>한국과학기술연구원 유전공학센터

\*서울대학교 의과대학 생화학과

**ABSTRACT:** The preS2 sequence of an *adr* hepatitis B virus was cloned and expressed in *Escherichia coli* as a  $\beta$ -galactosidase fusion polypeptide. Recombinant preS2 product interacted with the preS2-specific monoclonal antibody H8 which was induced by surface antigen particles isolated from a Korean hepatitis patient. The H8 showed only a minor cross-reactivity with recombinant preS2 product of *adw*2 subtype. Determination of nucleotide sequence of the *adr* preS2 revealed that twelve amino acid residue substitutions between *adr* and *adw*2 subtype sequences. The antigenic determinant to H8 must include some of these differences.

**KEY WORDS** □ preS2, monoclonal antibody,  $\beta$ -galactosidase-preS2 fusion

Three different envelope proteins are encoded by the 'S' open reading frame of the hepatitis B virus (HBV) genome. These are the major (S), middle (M), and large (L) proteins (Cattaneo *et al.*, 1983). Translation of these envelope proteins starts from three different initiation codons (Stibbe and Gerlich, 1983; Heerman *et al.*, 1984). The S protein, 226 amino acids long, is encoded by the S gene. The M protein, 281 amino acids long, is encoded by the preS2 plus S sequences. The L proteins, 400 (*ad* subtypes) or 389 (*ay* subtypes) amino acids long, is encoded by the entire preS (preS1 and preS2) plus S sequences. Immunological properties of these surface antigens are the basis of classifying virus serotypes (Le Bouvier

and Williams, 1975). Although preS2-containing M and L proteins are not abundantly present in hepatitis B virus particles (Heerman *et al.*, 1984), the preS2 region has been shown to be immunodominant (Neurath *et al.*, 1984; Milich *et al.*, 1985; Neurath *et al.*, 1985) and be able to elicit protective immunity in animals (Itoh *et al.*, 1986). PreS2 epitope was also indicated as one of the epitopes inducing neutralizing antibodies (Budkowska *et al.*, 1986). Knowledge of neutralizing epitopes is crucial in developing strategies for rational vaccine and anti-viral drug design. As a preliminary step towards this goal, we constructed plasmid systems of overexpressing preS2 peptide in *E. coli*. The antigenic properties of recom-

<sup>§</sup>To whom correspondence should be addressed.

binant preS2 were examined with an anti-preS2 monoclonal antibody.

## MATERIALS AND METHODS

### Materials

Restriction enzymes, *E. coli* DNA polymerase I large fragment (Klenow enzyme), T4 DNA ligase were purchased from New England Biolabs, Bethesda Research Laboratories, or Promega Corporation. ATP, [ $\alpha$ - $^{32}$ P]dATP, dNTPs, and DNA sequencing kit were purchased from Amersham. Ampicillin, bovine serum albumin, isopropyl- $\beta$ -D-thiogalactopyranoside (IPTG), 5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactoside (XGal) and 4-chloro-1-naphthol were from Sigma Chemical Company. Peroxidase-conjugated anti-mouse IgG was purchased from Kirkegaard and Perry Laboratories. All other chemicals used were reagent grade.

### Strains and plasmids

*E. coli* JM109 [*recA1*, *endA1*, *gyrA96*, *thi*, *hsdR17*, *supE44*, *relA1*,  $\Delta$ (*lac-proAB*), *F'*(*traD36*, *proA*<sup>+</sup>*B*<sup>+</sup>, *lacI*<sup>q</sup>, *lacZ*  $\Delta$ M15)] was used as a host strain for cloning. Plasmid pHBV-315 carrying the HBV genome inserted at the *Bam*HI site of pBR322 (Kim and Kang, 1984) was a kind gift from Hyen Sam Kang. Plasmid pUC9 and pUC19 were purchased from Pharmacia P-L Biochemicals. Plasmids pCMHB20 and pCMHB30 were described previously (Park *et al.*, 1989) which encoded preS2 sequence of *adw2* serotype as a fusion protein with truncated  $\beta$ -galactosidase.

### Oligonucleotides

All the oligonucleotides were synthesized with an automated DNA synthesizer (Beckman System Plus). Modified deprotection was adopted to simplify the procedure by employing a single treatment of concentrated  $\text{NH}_4\text{OH}$  at 50°C for 12 h. Full length DNA was purified by polyacrylamide-urea gel electrophoresis (Lo *et al.*, 1984).

### Monoclonal antibodies specific to preS2 region of hepatitis B surface antigen

Details of preparation of monoclonal antibody which was specific to preS2 sequence of *adr* hepatitis B surface antigen (HBsAg) was previously described (Chung and Kim, 1987). In brief, the antibody was induced by 22 nm HBsAg particles isolated from hepatitis patient serum. Antibodies were purified by HBsAg-affinity column chromatography and preS-specific antibodies were screened on the criteria that preS antigenicity is lost after digestion of HBsAg with pepsin. One out of 52 exhibited the properties

described above and was named H8. Specific recognition of H8 to preS2 was then confirmed by immunoblotting to both M and L proteins of surface proteins, but not to S protein.

### Cloning procedures

All the enzymatic reaction conditions and cloning procedures were performed as described by Maniatis *et al.* (1982).

### Determination of nucleotide sequences

Dideoxy chain termination method (Sanger *et al.*, 1977) was carried out using supercoiled double-stranded plasmid DNA as a template (Chen and Seeburg, 1985).

### Electrophoresis and Western blotting

SDS-polyacrylamide gel electrophoresis was carried out as described (Laemmli, 1970). Antigenicity of preS2 was detected by Western blotting method (Towbin *et al.*, 1979) with preS2-specific monoclonal antibody H8. The peroxidase-conjugated anti-mouse IgG was used as a second antibody.

## RESULTS

### Construction of expression plasmids encoding preS2 of HBsAg

Plasmid pCMHB20 and pCMHB30 were previously constructed to overproduce preS2 peptide of *adw2* subtype as a  $\beta$ -galactosidase fusion polypeptide, which carried with *tac* promoter, *lacZ* sequence encoding N-terminal 208 and 293 amino acid residues of  $\beta$ -galactosidase, respectively (Park *et al.*, 1989). In order to overproduce *adr* subtype preS2 region, expression vectors were constructed as shown in Fig. 1. The 157 bp *Dde*I-*Ava*II fragment of preS2 region was isolated from pHBV-315 and ligated with two synthetic linkers to provide missing residues and stop codon. The 189 bp ligation product was then cloned into pUC9 to yield pUC9R, and from this a 176 bp DNA fragment of *adr* preS2 sequence was isolated and inserted into pUC19 to yield pUC19R. The *Xba*I-*Hind*III fragment of pUC19R was then substituted for the *Xba*I-*Hind*III of pCMHB20 to yield pCMHB(R)20. The resulting plasmid was identical to pCMHB20 except that *adr* preS2 region was substituted for *adw2* subtype. Plasmid pCMHB(R)30 was constructed by inserting a 243 bp *Xba*I fragment of *lacZ* isolated from pCMHB30 into pCMHB(R)20 (Fig. 1).

### Antigenic properties of $\beta$ -galactosidase-preS2 fusion proteins synthesized in *E. coli*

To express  $\beta$ -galactosidase-preS2 fusion proteins in *E. coli*, recombinant cells harboring appropriate





Fig. 1. Construction of *adr* subtype *preS2* expression vectors.

A 157 bp DdeI-AvaII fragment encoding *preS2* sequence was ligated with synthetic oligonucleotide linker III and IV. The resulting 185 bp fragment containing XhoI and HindIII adaptors at 5'- and 3'-end, respectively, was cloned at SalI and HindIII sites of pUC9 to yield pUC9R. The 176 bp fragment of *adr preS2* sequence was obtained from pUC9R by HindIII and XhoI partial digestion and then the fragment was inserted into pUC19 between SalI and HindIII site to yield pUC19R. The XbaI-HindIII fragment of pUC19R was then substituted for the XbaI-HindIII sites of pCMHB20 to yield pCMHB(R)20. To construct pCMHB(R)30, pCMHB30 was digested with XbaI and the isolated 243 bp fragment was inserted into XbaI site of pCMHB(R)20.

plasmids were grown and the synthesis of the fusion proteins was induced. The culture lysates were analyzed on SDS-polyacrylamide gel electrophoresis. As shown in Fig. 2a, the transformants harboring pCMHB(R)20 and pCMHB(R)30 produced fusion proteins of expected molecular size (lanes 7 and 9) with a yield of 50% of total cellular proteins, just as

the cells harboring pCMHB20 and pCMHB30 (lanes 3 and 5). In order to confirm that the fusion proteins encoded by pCMHB(R)20 and pCMHB(R)30 carried the *adr* subtype *preS2* sequence, Western blot analysis was performed with anti-*preS2* monoclonal antibody H8, which was induced by *adr* subtype HBsAg particles. Results in Fig. 2b shows that only the fu-




**Fig. 2.** Synthesis of  $\beta$ -galactosidase-preS2 fusion proteins and immunoblotting of preS2 in fusion proteins.

(a) Recombinant *E. coli* JM109 cells harboring pCMHB20, pCMHB30, pCMHB(R)20, pCMHB(R)30 plasmids were grown at 37°C and the synthesis of recombinant proteins was induced at an early log phase ( $A_{600} = 0.3$ ) by adding 2 mM IPTG. Cells were further incubated at 37°C for 3 h and the lysates were analyzed on 10% SDS-polyacrylamide gel electrophoresis. Protein bands were visualized by staining with Coomassie Brilliant Blue. Lane 1 shows molecular weight markers; from the top phosphorylase (98,400), bovine serum albumin (66,200), ovalbumin (45,000), carbonic anhydrase (31,000), soybean trypsin inhibitor (21,500), and lysozyme (14,400). Symbols, - and + indicates before and after induction of synthesis of recombinant proteins, respectively. Plasmids carried in each recombinant cells are also indicated: 1, pCMHB20; 2, pCMHB30; 3, pCMHB(R)20; 4, pCMHB(R)30. (b) Western blotting of (a). Immunoblotting was performed with the monoclonal antibody H8 and peroxidase-conjugated anti-mouse IgG antibody.

sion proteins encoded by pCMHB(R)20 and pCMHB(R)30 exhibited a specific interaction with H8 (lanes 7 and 9). The proteins encoded by pCMHB20 and pCMHB30 showed only a weak interaction with the same antibody.

#### Nucleotide Sequence Determination of an *adr* PreS2

The difference in antigenic properties seen in Fig. 2b of *adr* and *adw2* preS2 fusion polypeptides must reside in amino acid sequence variations between two subtypes. The nucleotide sequence of *adw2* preS2 had been reported previously (Valenzuela *et al.*, 1979). In order to identify the variation in our *adr* preS2 sequence cloned, the 157 bp DdeI-AvaII fragment (Fig. 1) containing most of preS2 was sequenced. To determine the rest of 3' portion of preS2 absent in the 157 bp fragment, a 640 bp BstEII-HincII fragment containing complete sequence of preS2 and 5' part of S was isolated from pHBV-315 and sequenced from 3' end. Fig. 3 shows the result of nucleotide sequence determination and the amino acid sequence deduced from this was shown in Fig. 4. The sequence we determined was different from those of three other *adr* serotype reported previously by Ono *et al.*, (1983), Fujiyama *et al.* (1983), and Kim and Rho (1988). Compared with the preS2 sequence of Ono *adr*, our sequence carried only two nucleotide variations (Fig. 3) without changing the amino acid sequence (Fig. 4). In comparison with preS2 sequences of Fujiyama and Kim, one and three amino acid residue substitutions were revealed, respectively. Many nucleotide variations were seen in comparison with the sequence of *adw* subtypes (Ono *et al.*, 1983; Valenzuela *et al.*, 1979), each of which yielded 12



**Fig. 3.** Nucleotide sequence determined for an *adr* subtype preS2 and its comparison with those of other preS2 reported previously.

1, *adr* subtype determined in this study; 2, *adr* subtype (Ono *et al.*, 1983); 3, *adr* subtype (Fujiyama *et al.*, 1983); 4, *adr* subtype (Kim *et al.*, 1988); 5, *adw* subtype (Ono *et al.*, 1983); 6, *adw2* subtype (Valenzuela *et al.*, 1979).





## 적 요

*adr* 아형 B형 간염바이러스의 preS2 염기서열을 베타갈락토시다제 유전자에 연결시켜 클로닝한 후, 융합단백질의 형태로 대장균에서 발현시켰다. 한국인 간염환자로부터 분리된 표면항원으로 유도한 단일클론항체 H8는 preS2에 특이성을 지니고 있으며, 상기의 융합단백질과 특이적으로 결합하였다. 이 단일클론항체는 *adw*2아형 preS2 융합단백질과는 단지 낮은 수준의 결합성을 보여주었는데, 이와 같은 단일클론항체 H8의 *adr* 아형과 *adw*2아형에 대한 결합성의 차이는 preS2 부위의 아미노산 차이에 기인한다고 볼 수 있다.

## ACKNOWLEDGEMENT

This work was partially supported by a grant (F80150) from a Korean Ministry of Science and Technology to M.-H. Yu.

## REFERENCES

1. Budkowska, A., M.-M. Riottot, P. Dubreuil, Y. Lazizi, C. Brechot, E. Sobczak, M.-A. Petit and J. Pillot, 1986. Monoclonal antibody recognizing pre-S (2) epitope of hepatitis B virus: Characterization of pre-S(2) antibody. *J. Med. Virol.* **20**, 111-125.
2. Cattaneo, R., H. Will, N. Hernandez and H. Schaller, 1983. Signals regulating hepatitis B surface antigen transcription. *Nature*, **305**, 336-338.
3. Chen, E.Y. and P.H. Seeburg, 1985. Supercoiling sequencing: A fast and simple method for sequencing plasmid. *DNA*, **4**, 165-170.
4. Chung, H.K. and S.R. Kim, 1987. Production of monoclonal antibody to hepatitis B surface antigen and its application to radioimmunoassay. *Recent progress in molecular biology and genetic engineering in Korea*, **1**, 165-172.
5. Fujiyama, A., A. Miyahara, C. Nozaki, T. Yoneyama, N. Ohtomo and K. Matsubara, 1983. Cloning and structural analysis of hepatitis B virus DNAs, subtype *adr*. *Nucleic Acids Res.* **11**, 4601-4610.
6. Gerin, J.L., H. Alexander, J.W.-K. Shih, R.H. Purcell, G. Dapolito, R. Engle, N. Green, J.G. Sutcliffe, T.M. Shinnick and R.A. Lerner, 1983. Chemically synthesized peptides of hepatitis B surface antigen duplicate the d/y specificities and induce subtype-specific antibodies in chimpanzees. *Proc. Natl. Acad. Sci. USA.* **80**, 2365-2369.
7. Heerman, K.H., U. Goldmann, W. Schwartz, T. Seyffarth, H. Baumgarten and W.H. Gerlich, 1984. Large surface proteins of hepatitis B virus containing the pre-S sequence. *J. Virol.* **52**, 396-402.
8. Hopp, T.P. and K.R. Woods, 1981. Prediction of protein antigenic determinants from amino acid sequences. *Proc. Natl. Acad. Sci. USA.* **78**, 3824-3828.
9. Itoh, Y., E. Takai, H. Ohnuma, K. Kitajima, F. Tsuda, A. Machida, S. Mishiho, T. Nakamura, Y. Miyakawa and M. Mayumi, 1986. A synthetic peptide vaccine involving the preS2 region of hepatitis B virus: protective efficacy in chimpanzees. *Proc. Natl. Acad. Sci. USA.* **83**, 9174-9178.
10. Kim, K.T., S.W. Hyun, Y.S. Kim and H.M. Rho, 1988. Complete nucleotide sequence of Hepatitis B Virus (subtype *adr*). *Kor. Biochem. J.* **21**, 319-331.
11. Kim, Y.S. and H.S. Kang, 1984. Cloning and expression of hepatitis B virus surface antigen gene. *Kor. Biochem. J.* **17**, 70-79.
12. Laemmli, U.K., 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227**, 680-685.
13. Le Bouvier, G.L. and A. Williams, 1975. Serotypes of hepatitis B antigen (HBsAg): The problem of new determinants, as exemplified by "t". *Am. J. Med. Sci.* **270**, 165-171.
14. Lo, K.-M., S.S. Jones, N.R. Hackett, and H.G. Khorana, 1984. Specific amino acid substitutions in bacteriophage T4: Replacement of a restriction fragment in the structural gene by synthetic DNA fragments containing altered codons. *Proc. Natl. Acad. Sci. USA.* **81**, 2285-2289.
15. Maniatis, T., E.F. Fritsch and J. Sambrook, 1982. Molecular cloning. Cold Spring Harbor Lab., Cold Spring Harbor. New York.
16. Milich, D.R., G.B. Thornton, A.R. Neurath, S.B.H. Kent, M.-I. Michel, P. Tiollais and F.V. Chiasri, 1985. Enhanced immunogenicity of the preS2 region of hepatitis B surface antigen. *Science* **228**, 1195-1199.
17. Neurath, A.R., S.B.H. Kent and N. Strick, 1984. Location and chemical synthesis of a preS gene coded immunodominant epitope of hepatitis B virus. *Science* **224**, 392-394.
18. Neurath, A.R., S.B.H. Kent, N. Strick, P. Taylor and C.E. Stevens, 1985. Hepatitis B virus contains preS gene encoded domains. *Nature* **315**, 154-156.
19. Park, C.K., S.H. Lee, Y.C. Choi and M.-H. Yu, 1989. Oligonucleotide-directed mutagenesis of two methionine residues in recombinant  $\beta$ -galactosidase preS2 fusion proteins. *Kor. Biochem. J.* **22**, 38-44.
20. Peterson, D.L., D.A. Paul, J. Lam, I.I.E. Tribby and D.T. Achord, 1984. Antigenic structure of hepatitis B surface antigen: Identification of the "d" subtype determinant by chemical modification and use of monoclonal antibodies. *J. Immunol.* **132**, 920-927.
21. Sanger, F., S. Nicklen and A.R. Coulson, 1977. DNA sequencing with chain termination inhibitors. *Proc. Natl. Acad. Sci. USA.* **74**, 5463-5467.
22. Stibbe, W. and W.H. Gerlich, 1983. Structural relationships between minor and major proteins of hepatitis B surface antigen. *J. Virol.* **46**, 626-628.

23. **Towbin, H., T. Staehelin and J. Gordon**, 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. *Proc. Natl. Acad. Sci. USA.* **76**, 4350-4354.
24. **Valenzuela, P., P. Gray, M. Quiroga, J. Zaldivar, H.M. Goodman and W. Rutter**, 1979. Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen. *Nature* **280**, 815-819.
25. **Westhof, E., D. Altschuh, D. Moras, A.C. Bloomer, A. Mondragon, A. Klug and M.H.V. Van Regenmortel**, 1984. Correlation between segmental mobility and the location of antigenic determinants in proteins. *Nature* **311**, 123-126.

(Received January 9, 1990)

(Accepted March 2, 1990)